Review Potential of Phytomedicine in Benefiting Both Long COVID and Acute Coronary Syndromes: A State-of-the-art Review, 2025, Jiang

Dolphin

Dolphin

Senior Member (Voting Rights)
https://www.xiahepublishing.com/2472-0712/ERHM-2024-00043

Potential of Phytomedicine in Benefiting Both Long COVID and Acute Coronary Syndromes: A State-of-the-art Review
  • Review Article
  • OPEN ACCESS
    Xiao Jiang1#, Yiran Lu2#, Yu Ding2#, Yuanyuan Liu3, Zhen Zhao1, Peizhong Liu1, Chuangpeng Li1, Song He2, Qing Zhang2, Rongyuan Yang1* and Qing Liu1*
Exploratory Research and Hypothesis in Medicine 2025;10(2):97-105

doi: 10.14218/ERHM.2024.00043

Abstract

Acute coronary syndrome (ACS) in patients with SARS-CoV-2 infection is primarily driven by inflammation-induced myocardial injury through both direct and indirect mechanisms.

Effective clinical management requires a dual approach: addressing cardiovascular lesions while also mitigating virus-induced local and systemic inflammation.

This comprehensive approach is essential for improving the diagnosis and treatment of SARS-CoV-2-associated ACS.

Emerging evidence highlights the potential of myocardial protective agents, including angiotensin-converting enzyme 2-modulating drugs and traditional Chinese medicine, which not only stabilize plaques and improve endothelial function but also confer cardioprotective effects.

Furthermore, advancements in nanotechnology offer promising strategies for targeted therapy—particularly through angiotensin-converting enzyme 2 receptor modulation—by enhancing the precision and efficacy of herbal medicine delivery.

This review explores the complex interplay between SARS-CoV-2 infection and ACS pathogenesis, and evaluates the therapeutic potential of pharmacological, herbal, and nanotechnology-based interventions in managing this multifaceted condition.

Keywords
Long COVID, Acute coronary syndromes, ACS, Phytomedicin, Nanotechnology, ACE2 receptor, Lipid nanoparticles
 
https://www.eurekalert.org/news-releases/1084870

News Release 22-May-2025
Potential of phytomedicine in benefiting both long COVID and acute coronary syndromes
Peer-Reviewed Publication

Xia & He Publishing Inc.


image:

This leads to systemic cytokine storms, promotes thrombosis, and accelerates ACS. ACE2, angiotensin-converting enzyme 2; ACS, acute coronary syndrome; IL-6, interleukin-6.

view more


Credit: Qing Liu, Rongyuan Yang, Xiao Jiang, Yiran Lu, Yu Ding

Acute coronary syndrome (ACS) in patients with SARS-CoV-2 infection represents a critical intersection of viral-induced inflammation and cardiovascular pathology. This review explores the dual mechanisms driving SARS-CoV-2-associated ACS and evaluates emerging therapeutic strategies, including phytomedicine and nanotechnology, to address both viral and cardiovascular complications.

SARS-CoV-2 and ACS Pathogenesis
SARS-CoV-2 infection exacerbates ACS through systemic inflammation, endothelial dysfunction, and plaque destabilization. The virus triggers a cytokine storm, marked by elevated inflammatory biomarkers (e.g., IL-6, C-reactive protein), which promote platelet activation, thrombus formation, and coronary microvascular dysfunction. These processes are amplified by hypoxia and hemodynamic instability, creating a perfect storm for myocardial injury.

ACE2 Receptor: A Double-Edged Sword
The angiotensin-converting enzyme 2 (ACE2) receptor, essential for viral entry, is abundantly expressed in cardiovascular tissues. SARS-CoV-2 binding to ACE2 disrupts the renin-angiotensin system, exacerbating endothelial injury, vasoconstriction, and pro-thrombotic states. This receptor-mediated damage underlies both direct myocardial injury and indirect ischemic events, positioning ACE2 modulation as a therapeutic target.

Myocardial Protective Agents
While ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are debated due to their potential ACE2-upregulating effects, melatonin emerges as a promising adjunct. It enhances nitric oxide bioavailability, stabilizes plaques, and mitigates oxidative stress, offering cardioprotection during viral-induced inflammation.

Herbal Medicine: Bridging Antiviral and Cardioprotective Effects
Traditional Chinese medicine (TCM) demonstrates dual efficacy against SARS-CoV-2 and ACS:

  • Licorice (Glycyrrhiza spp.): Glycyrrhizic acid inhibits viral replication via NF-κB and MAPK pathways while reducing oxidative damage through Nrf2 activation.

  • Lianhua Qingwen Granules: This formulation blocks ACE2-S protein binding, suppresses cytokine storms (IL-6, TNF-α), and improves endothelial function.

  • Astragalus membranaceus and Honeysuckle: These herbs modulate immune responses, inhibit viral entry, and attenuate fibrosis, showcasing synergy in COVID-19 and cardiovascular management.
Non-Herbal Interventions
Peptide fusion inhibitors (e.g., EK1C4) and IL-1 antagonists (anakinra) show promise in reducing thromboembolic events and ACS incidence. Anakinra, in particular, improves survival in severe COVID-19 by curbing hyperinflammation, though its efficacy in advanced respiratory failure remains contentious.

Nanotechnology: Precision in Therapy and Prevention
Nanoparticle platforms revolutionize COVID-19 management:

  • mRNA Vaccines: Lipid nanoparticles in Pfizer-BioNTech and Moderna vaccines enhance mRNA stability and immunogenicity, achieving >95% efficacy.

  • Nanoceria (NC): These antioxidant nanoparticles mitigate pulmonary fibrosis and acute respiratory distress syndrome (ARDS) via TGF-β inhibition.

  • Silver Nanoparticles (AgNPs): AgNPs disrupt viral replication and reduce cytokine storms, though toxicity and biodegradability challenges persist.
    Nanocarriers functionalized with ACE2-targeting ligands enable precise delivery of antiviral phytochemicals, enhancing therapeutic specificity.
Future Directions
Key priorities include:

  1. Clinical Trials: Large-scale studies to standardize TCM dosages and validate long-term safety.

  2. Mechanistic Insights: Cryo-EM and molecular docking to elucidate herb-ACE2 interactions.

  3. Nanotech Optimization: Improving nanoparticle targeting and clearance mechanisms.

  4. Multi-Omics Integration: Identifying biomarkers for personalized phytotherapy.
Conclusion
SARS-CoV-2-associated ACS demands integrated strategies addressing viral pathogenesis and cardiovascular injury. Phytomedicine, exemplified by TCM, offers multi-targeted benefits, while nanotechnology enhances drug precision. Despite challenges in nanoparticle toxicity and herb standardization, these approaches herald a new era in managing COVID-19 complications. Bridging traditional wisdom with cutting-edge science could redefine therapeutic paradigms, emphasizing safety, efficacy, and holistic care in post-pandemic cardiology.



Full text:

https://www.xiahepublishing.com/2472-0712/ERHM-2024-00043



The study was recently published in the Exploratory Research and Hypothesis in Medicine.

Exploratory Research and Hypothesis in Medicine (ERHM) publishes original exploratory research articles and state-of-the-art reviews that focus on novel findings and the most recent scientific advances that support new hypotheses in medicine. The journal accepts a wide range of topics, including innovative diagnostic and therapeutic modalities as well as insightful theories related to the practice of medicine. The exploratory research published in ERHM does not necessarily need to be comprehensive and conclusive, but the study design must be solid, the methodologies must be reliable, the results must be true, and the hypothesis must be rational and justifiable with evidence.



Follow us on X: @xiahepublishing

Follow us on LinkedIn: Xia & He Publishing Inc.

Journal
Exploratory Research and Hypothesis in Medicine

DOI
10.14218/ERHM.2024.00043

Article Title
Potential of Phytomedicine in Benefiting Both Long COVID and Acute Coronary Syndromes: A State-of-the-art Review

Article Publication Date
13-May-2025
 
You must log in or register to reply here.
Back
Top